• $373.5M
    Market Cap
  • 200.33%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 31
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney reported full-year 2025 financial results with $270.0 million in cash and cash equivalents, supporting operations into mid-2027. The company achieved significant milestones including FDA alignment on an accelerated approval pathway for rilparencel using eGFR slope as a surrogate endpoint, positive Phase 2 REGEN-007 results, and strong enrollment momentum in the Phase 3 PROACT 1 study. The company expects to complete enrollment for the accelerated approval analysis by mid-2026 and deliver pivotal topline results in Q2 2027.

03/18/2026, 4:00 PM • GlobeNewswire

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

ProKidney presented Phase 2 trial results showing rilparencel potentially slows chronic kidney disease progression in diabetic patients, with statistically significant improvements in estimated glomerular filtration rate (eGFR) slope and no serious adverse events.

11/06/2025, 11:00 AM • GlobeNewswire

Peers

  • TNGX
    TANGO THERAPETCS
    $28.39-0.39%
    Market Cap$4.6B
    1-Year Change+435.71%
  • TYRA
    TYRA BIOSCIS
    $30.06-0.27%
    Market Cap$1.8B
    1-Year Change+210.40%
  • NBTX
    NANOBIOTIX SP ADS
    $36.60+3.89%
    Market Cap$1.8B
    1-Year Change+697.96%
  • BCAX
    BICARA THERAP
    $25.00+1.83%
    Market Cap$1.6B
    1-Year Change+167.43%
  • SEPN
    SEPTERNA
    $36.57+4.94%
    Market Cap$1.6B
    1-Year Change+230.96%
  • SVRA
    SAVARA
    $5.72+0.53%
    Market Cap$1.2B
    1-Year Change+163.43%
  • EYPT
    EyePoint
    $14.80+7.79%
    Market Cap$1.2B
    1-Year Change+65.82%
  • KURA
    Kura Oncology
    $10.31-0.48%
    Market Cap$919.7M
    1-Year Change+76.49%
  • PRME
    PRIME MEDICINE
    $3.31-1.78%
    Market Cap$608.7M
    1-Year Change+56.02%
  • RZLT
    REZOLUTE
    $4.89-5.05%
    Market Cap$495.9M
    1-Year Change+27.79%

Statistics

More
Day Range
$1.80
$1.93
$1.82
1-Year Range
$0.57
$5.18
$1.82
Latest Close$1.82
Change
-$0.01 (-0.55%)
Volume728,575
Market Cap$373.5M
Shares Outstanding205.2M
P/E (TTM)-3.45
Diluted EPS (TTM)-$0.53
Enterprise Value$271.6M

Information as of 06/22/2026

Company Profile

PROKIDNEY CORP
https://prokidney.com
$373.5M
Market Cap
-$72.3M
Net Income
Sector: Healthcare
Industry: Biotechnology
2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States, 27103
336 999 7019

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key Executives

  • Bruce Culleton
  • Todd C. Girolamo
  • James Coulston
  • Ulrich Ernst
  • Richard Williams

Current Ownership Distribution

  • Institutions310.0M (65.70%)
  • Insiders101.7M (21.54%)
  • Mutual Funds60.2M (12.75%)
  • Other0 (0.00%)